Carl P Walther1, Aravind Chandra2, Sankar D Navaneethan1,3. 1. Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine. 2. Department of Medicine, Baylor College of Medicine. 3. Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: Observational and interventional studies provide conflicting evidence regarding optimal blood pressure (BP) control in persons with chronic kidney disease (CKD). Recent publications provide additional information to inform therapeutic decision-making. RECENT FINDINGS: Targeting SBP to less than 120 mmHg, versus less than 140 mmHg, decreased cardiovascular events and all-cause mortality in persons with nondiabetic CKD. A meta-analysis of trials testing blood pressure management among nondialysis-dependent CKD patients (15 924 total patients) found more intensive therapies generally reduced mortality in all subgroups. Observational studies demonstrate that low SBP is associated with higher mortality in CKD. A recent report suggests that this is because of death from cardiovascular and noncardiovascular and nonmalignant causes, whereas higher BP is associated with death from cardiovascular causes. The shape of association between BP and cardiovascular and noncardiovascular events also appears to vary depending on baseline risk factors. Furthermore, BP measurement methodology may differ importantly between observational and interventional studies. SUMMARY: We review and summarize observational and interventional literature relating BP parameters to key clinical outcomes in persons with CKD. Apart from the inherent differences between these study designs, the disparate findings from trials and observational studies may be because of differences in patient characteristics and BP measurement techniques.
PURPOSE OF REVIEW: Observational and interventional studies provide conflicting evidence regarding optimal blood pressure (BP) control in persons with chronic kidney disease (CKD). Recent publications provide additional information to inform therapeutic decision-making. RECENT FINDINGS: Targeting SBP to less than 120 mmHg, versus less than 140 mmHg, decreased cardiovascular events and all-cause mortality in persons with nondiabetic CKD. A meta-analysis of trials testing blood pressure management among nondialysis-dependent CKDpatients (15 924 total patients) found more intensive therapies generally reduced mortality in all subgroups. Observational studies demonstrate that low SBP is associated with higher mortality in CKD. A recent report suggests that this is because of death from cardiovascular and noncardiovascular and nonmalignant causes, whereas higher BP is associated with death from cardiovascular causes. The shape of association between BP and cardiovascular and noncardiovascular events also appears to vary depending on baseline risk factors. Furthermore, BP measurement methodology may differ importantly between observational and interventional studies. SUMMARY: We review and summarize observational and interventional literature relating BP parameters to key clinical outcomes in persons with CKD. Apart from the inherent differences between these study designs, the disparate findings from trials and observational studies may be because of differences in patient characteristics and BP measurement techniques.
Authors: Csaba P Kovesdy; Anthony J Bleyer; Miklos Z Molnar; Jennie Z Ma; John J Sim; William C Cushman; L Darryl Quarles; Kamyar Kalantar-Zadeh Journal: Ann Intern Med Date: 2013-08-20 Impact factor: 25.391
Authors: Csaba P Kovesdy; Ahmed Alrifai; Elvira O Gosmanova; Jun Ling Lu; Robert B Canada; Barry M Wall; Adriana M Hung; Miklos Z Molnar; Kamyar Kalantar-Zadeh Journal: Clin J Am Soc Nephrol Date: 2016-04-21 Impact factor: 8.237
Authors: Shyamal Palit; Michel Chonchol; Alfred K Cheung; James Kaufman; Gerard Smits; Jessica Kendrick Journal: Clin J Am Soc Nephrol Date: 2015-05-15 Impact factor: 8.237
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Carmen A Peralta; Keith C Norris; Suying Li; Tara I Chang; Manjula K Tamura; Stacey E Jolly; George Bakris; Peter A McCullough; Michael Shlipak Journal: Arch Intern Med Date: 2012-01-09
Authors: Ilana B Richman; Michael Fairley; Mads Emil Jørgensen; Alejandro Schuler; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: JAMA Cardiol Date: 2016-11-01 Impact factor: 14.676
Authors: Carmen A Peralta; Leslie A McClure; Rebecca Scherzer; Michelle C Odden; Carole L White; Michael Shlipak; Oscar Benavente; Pablo Pergola Journal: Circulation Date: 2016-01-13 Impact factor: 29.690
Authors: Nisha Bansal; Charles E McCulloch; Feng Lin; Cassianne Robinson-Cohen; Mahboob Rahman; John W Kusek; Amanda H Anderson; Dawei Xie; Raymond R Townsend; Claudia M Lora; Jackson Wright; Alan S Go; Akinlolu Ojo; Arnold Alper; Eva Lustigova; Magda Cuevas; Radhakrishna Kallem; Chi-Yuan Hsu Journal: Kidney Int Date: 2016-10-04 Impact factor: 10.612
Authors: Alfred K Cheung; Mahboob Rahman; David M Reboussin; Timothy E Craven; Tom Greene; Paul L Kimmel; William C Cushman; Amret T Hawfield; Karen C Johnson; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Kaycee M Sink; Paul K Whelton; Jackson T Wright; Jan Basile; Srinivasan Beddhu; Udayan Bhatt; Tara I Chang; Glenn M Chertow; Michel Chonchol; Barry I Freedman; William Haley; Joachim H Ix; Lois A Katz; Anthony A Killeen; Vasilios Papademetriou; Ana C Ricardo; Karen Servilla; Barry Wall; Dawn Wolfgram; Jerry Yee Journal: J Am Soc Nephrol Date: 2017-06-22 Impact factor: 10.121